Voyager Therapeutics rises after Wedbush starts with 'outperform'

Voyager Therapeutics

29/11/2024 14:23

** Biotech company Voyager Therapeutics'  VYGR.O  shares
rise 6.9% to $6.18 premarket
    ** Wedbush analyst Yun Zhong starts coverage on stock with
"outperform" rating and PT at $11; previous Wedbush analyst
covering stock had a "neutral" rating and PT of $7
    ** The new PT is a 90.3% upside to the stock's last close
    ** Brokerage says positive data from VYGR's programs
targeting neurodegenerative disorders, including Alzheimer's and
ALS, have boosted their confidence
    ** Wedbush says shares are trading low, creating an
"attractive investment opportunity" despite the high risks of
early-stage treatments
    ** All ten brokerages rate the stock "buy" or higher; their
median PT is $18 - LSEG
    ** As of last close, stock has fallen 31.5% YTD
   

 (Reporting by Kamal Choudhury)
 ((Kamal.Choudhury@thomsonreuters.com;))